Table of Content

1 Report Overview
1.1 Anti-PD-1 MAb Definition
1.2 Market by Type
1.2.1 Global Anti-PD-1 MAb Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 40mg
1.2.3 100mg
1.2.4 200mg
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Anti-PD-1 MAb Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Melanoma Patients
1.3.3 Lung Cancer Patients
1.3.4 Lymphoma Patients
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Anti-PD-1 MAb Sales
2.1 Global Anti-PD-1 MAb Revenue Estimates and Forecasts 2018-2034
2.2 Global Anti-PD-1 MAb Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Anti-PD-1 MAb Revenue by Region
2.3.1 Global Anti-PD-1 MAb Revenue by Region (2018-2024)
2.3.2 Global Anti-PD-1 MAb Revenue by Region (2024-2034)
2.4 Global Anti-PD-1 MAb Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Anti-PD-1 MAb Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Anti-PD-1 MAb Sales Quantity by Region
2.6.1 Global Anti-PD-1 MAb Sales Quantity by Region (2018-2024)
2.6.2 Global Anti-PD-1 MAb Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Anti-PD-1 MAb Sales Quantity by Manufacturers
3.1.1 Global Anti-PD-1 MAb Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Anti-PD-1 MAb Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Anti-PD-1 MAb Sales in 2022
3.2 Global Anti-PD-1 MAb Revenue by Manufacturers
3.2.1 Global Anti-PD-1 MAb Revenue by Manufacturers (2018-2024)
3.2.2 Global Anti-PD-1 MAb Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-PD-1 MAb Revenue in 2022
3.3 Global Anti-PD-1 MAb Sales Price by Manufacturers
3.4 Global Key Players of Anti-PD-1 MAb, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-PD-1 MAb Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-PD-1 MAb, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-PD-1 MAb, Product Offered and Application
3.8 Global Key Manufacturers of Anti-PD-1 MAb, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Anti-PD-1 MAb Sales Quantity by Type
4.1.1 Global Anti-PD-1 MAb Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Anti-PD-1 MAb Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Anti-PD-1 MAb Sales Quantity Market Share by Type (2018-2034)
4.2 Global Anti-PD-1 MAb Revenue by Type
4.2.1 Global Anti-PD-1 MAb Historical Revenue by Type (2018-2024)
4.2.2 Global Anti-PD-1 MAb Forecasted Revenue by Type (2024-2034)
4.2.3 Global Anti-PD-1 MAb Revenue Market Share by Type (2018-2034)
4.3 Global Anti-PD-1 MAb Price by Type
4.3.1 Global Anti-PD-1 MAb Price by Type (2018-2024)
4.3.2 Global Anti-PD-1 MAb Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Anti-PD-1 MAb Sales Quantity by Application
5.1.1 Global Anti-PD-1 MAb Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Anti-PD-1 MAb Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Anti-PD-1 MAb Sales Quantity Market Share by Application (2018-2034)
5.2 Global Anti-PD-1 MAb Revenue by Application
5.2.1 Global Anti-PD-1 MAb Historical Revenue by Application (2018-2024)
5.2.2 Global Anti-PD-1 MAb Forecasted Revenue by Application (2024-2034)
5.2.3 Global Anti-PD-1 MAb Revenue Market Share by Application (2018-2034)
5.3 Global Anti-PD-1 MAb Price by Application
5.3.1 Global Anti-PD-1 MAb Price by Application (2018-2024)
5.3.2 Global Anti-PD-1 MAb Price Forecast by Application (2024-2034)
6 North America
6.1 North America Anti-PD-1 MAb Sales by Company
6.1.1 North America Anti-PD-1 MAb Revenue by Company (2018-2024)
6.1.2 North America Anti-PD-1 MAb Sales Quantity by Company (2018-2024)
6.2 North America Anti-PD-1 MAb Market Size by Type
6.2.1 North America Anti-PD-1 MAb Sales Quantity by Type (2018-2034)
6.2.2 North America Anti-PD-1 MAb Revenue by Type (2018-2034)
6.3 North America Anti-PD-1 MAb Market Size by Application
6.3.1 North America Anti-PD-1 MAb Sales Quantity by Application (2018-2034)
6.3.2 North America Anti-PD-1 MAb Revenue by Application (2018-2034)
6.4 North America Anti-PD-1 MAb Market Size by Country
6.4.1 North America Anti-PD-1 MAb Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Anti-PD-1 MAb Revenue by Country (2018-2034)
6.4.3 North America Anti-PD-1 MAb Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Anti-PD-1 MAb Sales by Company
7.1.1 Europe Anti-PD-1 MAb Sales Quantity by Company (2018-2024)
7.1.2 Europe Anti-PD-1 MAb Revenue by Company (2018-2024)
7.2 Europe Anti-PD-1 MAb Market Size by Type
7.2.1 Europe Anti-PD-1 MAb Sales Quantity by Type (2018-2034)
7.2.2 Europe Anti-PD-1 MAb Revenue by Type (2018-2034)
7.3 Europe Anti-PD-1 MAb Market Size by Application
7.3.1 Europe Anti-PD-1 MAb Sales Quantity by Application (2018-2034)
7.3.2 Europe Anti-PD-1 MAb Revenue by Application (2018-2034)
7.4 Europe Anti-PD-1 MAb Market Size by Country
7.4.1 Europe Anti-PD-1 MAb Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Anti-PD-1 MAb Revenue by Country (2018-2034)
7.4.3 Europe Anti-PD-1 MAb Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Anti-PD-1 MAb Sales by Company
8.1.1 China Anti-PD-1 MAb Sales Quantity by Company (2018-2024)
8.1.2 China Anti-PD-1 MAb Revenue by Company (2018-2024)
8.2 China Anti-PD-1 MAb Market Size by Type
8.2.1 China Anti-PD-1 MAb Sales Quantity by Type (2018-2034)
8.2.2 China Anti-PD-1 MAb Revenue by Type (2018-2034)
8.3 China Anti-PD-1 MAb Market Size by Application
8.3.1 China Anti-PD-1 MAb Sales Quantity by Application (2018-2034)
8.3.2 China Anti-PD-1 MAb Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Anti-PD-1 MAb Sales by Company
9.1.1 APAC Anti-PD-1 MAb Sales Quantity by Company (2018-2024)
9.1.2 APAC Anti-PD-1 MAb Revenue by Company (2018-2024)
9.2 APAC Anti-PD-1 MAb Market Size by Type
9.2.1 APAC Anti-PD-1 MAb Sales Quantity by Type (2018-2034)
9.2.2 APAC Anti-PD-1 MAb Revenue by Type (2018-2034)
9.3 APAC Anti-PD-1 MAb Market Size by Application
9.3.1 APAC Anti-PD-1 MAb Sales Quantity by Application (2018-2034)
9.3.2 APAC Anti-PD-1 MAb Revenue by Application (2018-2034)
9.4 APAC Anti-PD-1 MAb Market Size by Region
9.4.1 APAC Anti-PD-1 MAb Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Anti-PD-1 MAb Revenue by Region (2018-2034)
9.4.3 APAC Anti-PD-1 MAb Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-PD-1 MAb Sales by Company
10.1.1 Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Anti-PD-1 MAb Market Size by Type
10.2.1 Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Anti-PD-1 MAb Market Size by Application
10.3.1 Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Anti-PD-1 MAb Market Size by Country
10.4.1 Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Information
11.1.2 Bristol Myers Squibb Overview
11.1.3 Bristol Myers Squibb Anti-PD-1 MAb Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Bristol Myers Squibb Anti-PD-1 MAb Products and Services
11.1.5 Bristol Myers Squibb Anti-PD-1 MAb SWOT Analysis
11.1.6 Bristol Myers Squibb Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Anti-PD-1 MAb Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Merck Anti-PD-1 MAb Products and Services
11.2.5 Merck Anti-PD-1 MAb SWOT Analysis
11.2.6 Merck Recent Developments
11.3 Junshi Pharma
11.3.1 Junshi Pharma Company Information
11.3.2 Junshi Pharma Overview
11.3.3 Junshi Pharma Anti-PD-1 MAb Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Junshi Pharma Anti-PD-1 MAb Products and Services
11.3.5 Junshi Pharma Anti-PD-1 MAb SWOT Analysis
11.3.6 Junshi Pharma Recent Developments
11.4 Innovent Biologics Inc
11.4.1 Innovent Biologics Inc Company Information
11.4.2 Innovent Biologics Inc Overview
11.4.3 Innovent Biologics Inc Anti-PD-1 MAb Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Innovent Biologics Inc Anti-PD-1 MAb Products and Services
11.4.5 Innovent Biologics Inc Anti-PD-1 MAb SWOT Analysis
11.4.6 Innovent Biologics Inc Recent Developments
11.5 Hengrui Medicine
11.5.1 Hengrui Medicine Company Information
11.5.2 Hengrui Medicine Overview
11.5.3 Hengrui Medicine Anti-PD-1 MAb Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Hengrui Medicine Anti-PD-1 MAb Products and Services
11.5.5 Hengrui Medicine Anti-PD-1 MAb SWOT Analysis
11.5.6 Hengrui Medicine Recent Developments
11.6 Beijing Beigene
11.6.1 Beijing Beigene Company Information
11.6.2 Beijing Beigene Overview
11.6.3 Beijing Beigene Anti-PD-1 MAb Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Beijing Beigene Anti-PD-1 MAb Products and Services
11.6.5 Beijing Beigene Anti-PD-1 MAb SWOT Analysis
11.6.6 Beijing Beigene Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Anti-PD-1 MAb Value Chain Analysis
12.2 Anti-PD-1 MAb Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-PD-1 MAb Production Mode & Process
12.4 Anti-PD-1 MAb Sales and Marketing
12.4.1 Anti-PD-1 MAb Sales Channels
12.4.2 Anti-PD-1 MAb Distributors
12.5 Anti-PD-1 MAb Customers
13 Market Dynamics
13.1 Anti-PD-1 MAb Industry Trends
13.2 Anti-PD-1 MAb Market Drivers
13.3 Anti-PD-1 MAb Market Challenges
13.4 Anti-PD-1 MAb Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-PD-1 MAb Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of 40mg
Table 3. Major Manufacturers of 100mg
Table 4. Major Manufacturers of 200mg
Table 5. Major Manufacturers of Others
Table 6. Global Anti-PD-1 MAb Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Anti-PD-1 MAb Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Anti-PD-1 MAb Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Anti-PD-1 MAb Revenue Market Share by Region (2018-2024)
Table 10. Global Anti-PD-1 MAb Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Anti-PD-1 MAb Revenue Market Share by Region (2024-2034)
Table 12. Global Anti-PD-1 MAb Sales Quantity by Region: 2018 VS 2022 VS 2034 (KG)
Table 13. Global Anti-PD-1 MAb Sales by Region (2018-2024) & (KG)
Table 14. Global Anti-PD-1 MAb Sales Market Share by Region (2018-2024)
Table 15. Global Anti-PD-1 MAb Sales by Region (2024-2034) & (KG)
Table 16. Global Anti-PD-1 MAb Sales Market Share by Region (2024-2034)
Table 17. Global Anti-PD-1 MAb Sales Quantity by Manufacturers (2018-2024) & (KG)
Table 18. Global Anti-PD-1 MAb Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Anti-PD-1 MAb Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Anti-PD-1 MAb Revenue Share by Manufacturers (2018-2024)
Table 21. Global Anti-PD-1 MAb Price by Manufacturers 2018-2024 (USD/KG)
Table 22. Global Key Players of Anti-PD-1 MAb, Industry Ranking, 2021 VS 2022
Table 23. Global Anti-PD-1 MAb Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Anti-PD-1 MAb by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-PD-1 MAb as of 2022)
Table 25. Global Key Manufacturers of Anti-PD-1 MAb, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Anti-PD-1 MAb, Product Offered and Application
Table 27. Global Key Manufacturers of Anti-PD-1 MAb, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Anti-PD-1 MAb Sales Quantity by Type (2018-2024) & (KG)
Table 30. Global Anti-PD-1 MAb Sales Quantity by Type (2024-2034) & (KG)
Table 31. Global Anti-PD-1 MAb Sales Quantity Share by Type (2018-2024)
Table 32. Global Anti-PD-1 MAb Sales Quantity Share by Type (2024-2034)
Table 33. Global Anti-PD-1 MAb Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Anti-PD-1 MAb Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Anti-PD-1 MAb Revenue Share by Type (2018-2024)
Table 36. Global Anti-PD-1 MAb Revenue Share by Type (2024-2034)
Table 37. Anti-PD-1 MAb Price by Type (2018-2024) & (USD/KG)
Table 38. Global Anti-PD-1 MAb Price Forecast by Type (2024-2034) & (USD/KG)
Table 39. Global Anti-PD-1 MAb Sales Quantity by Application (2018-2024) & (KG)
Table 40. Global Anti-PD-1 MAb Sales Quantity by Application (2024-2034) & (KG)
Table 41. Global Anti-PD-1 MAb Sales Quantity Share by Application (2018-2024)
Table 42. Global Anti-PD-1 MAb Sales Quantity Share by Application (2024-2034)
Table 43. Global Anti-PD-1 MAb Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Anti-PD-1 MAb Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Anti-PD-1 MAb Revenue Share by Application (2018-2024)
Table 46. Global Anti-PD-1 MAb Revenue Share by Application (2024-2034)
Table 47. Anti-PD-1 MAb Price by Application (2018-2024) & (USD/KG)
Table 48. Global Anti-PD-1 MAb Price Forecast by Application (2024-2034) & (USD/KG)
Table 49. North America Anti-PD-1 MAb Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Anti-PD-1 MAb Sales Quantity by Company (2018-2024) & (KG)
Table 51. North America Anti-PD-1 MAb Sales Quantity by Type (2018-2024) & (KG)
Table 52. North America Anti-PD-1 MAb Sales Quantity by Type (2024-2034) & (KG)
Table 53. North America Anti-PD-1 MAb Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Anti-PD-1 MAb Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Anti-PD-1 MAb Sales Quantity by Application (2018-2024) & (KG)
Table 56. North America Anti-PD-1 MAb Sales Quantity by Application (2024-2034) & (KG)
Table 57. North America Anti-PD-1 MAb Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Anti-PD-1 MAb Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Anti-PD-1 MAb Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Anti-PD-1 MAb Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Anti-PD-1 MAb Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Anti-PD-1 MAb Sales Quantity by Country (2018-2024) & (KG)
Table 63. North America Anti-PD-1 MAb Sales Quantity by Country (2024-2034) & (KG)
Table 64. Europe Anti-PD-1 MAb Sales Quantity by Company (2018-2024) & (KG)
Table 65. Europe Anti-PD-1 MAb Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Anti-PD-1 MAb Sales Quantity by Type (2018-2024) & (KG)
Table 67. Europe Anti-PD-1 MAb Sales Quantity by Type (2024-2034) & (KG)
Table 68. Europe Anti-PD-1 MAb Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Anti-PD-1 MAb Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Anti-PD-1 MAb Sales Quantity by Application (2018-2024) & (KG)
Table 71. Europe Anti-PD-1 MAb Sales Quantity by Application (2024-2034) & (KG)
Table 72. Europe Anti-PD-1 MAb Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Anti-PD-1 MAb Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Anti-PD-1 MAb Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Anti-PD-1 MAb Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Anti-PD-1 MAb Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Anti-PD-1 MAb Sales Quantity by Country (2018-2024) & (KG)
Table 78. Europe Anti-PD-1 MAb Sales Quantity by Country (2024-2034) & (KG)
Table 79. China Anti-PD-1 MAb Sales Quantity by Company (2018-2024) & (KG)
Table 80. China Anti-PD-1 MAb Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Anti-PD-1 MAb Sales Quantity by Type (2018-2024) & (KG)
Table 82. China Anti-PD-1 MAb Sales Quantity by Type (2024-2034) & (KG)
Table 83. China Anti-PD-1 MAb Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Anti-PD-1 MAb Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Anti-PD-1 MAb Sales Quantity by Application (2018-2024) & (KG)
Table 86. China Anti-PD-1 MAb Sales Quantity by Application (2024-2034) & (KG)
Table 87. China Anti-PD-1 MAb Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Anti-PD-1 MAb Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Anti-PD-1 MAb Sales Quantity by Company (2018-2024) & (KG)
Table 90. APAC Anti-PD-1 MAb Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Anti-PD-1 MAb Sales Quantity by Type (2018-2024) & (KG)
Table 92. APAC Anti-PD-1 MAb Sales Quantity by Type (2024-2034) & (KG)
Table 93. APAC Anti-PD-1 MAb Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Anti-PD-1 MAb Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Anti-PD-1 MAb Sales Quantity by Application (2018-2024) & (KG)
Table 96. APAC Anti-PD-1 MAb Sales Quantity by Application (2024-2034) & (KG)
Table 97. APAC Anti-PD-1 MAb Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Anti-PD-1 MAb Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Anti-PD-1 MAb Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Anti-PD-1 MAb Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Anti-PD-1 MAb Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Anti-PD-1 MAb Sales Quantity by Region (2018-2024) & (KG)
Table 103. APAC Anti-PD-1 MAb Sales Quantity by Region (2024-2034) & (KG)
Table 104. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Company (2018-2024) & (KG)
Table 105. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Type (2018-2024) & (KG)
Table 107. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Type (2024-2034) & (KG)
Table 108. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Application (2018-2024) & (KG)
Table 111. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Application (2024-2034) & (KG)
Table 112. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Country (2018-2024) & (KG)
Table 118. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity by Country (2024-2034) & (KG)
Table 119. Bristol Myers Squibb Company Information
Table 120. Bristol Myers Squibb Description and Overview
Table 121. Bristol Myers Squibb Anti-PD-1 MAb Sales Quantity (KG), Revenue (US$ Million), Average Selling Price (ASP) (USD/KG) and Gross Margin (2018-2024)
Table 122. Bristol Myers Squibb Anti-PD-1 MAb Product and Services
Table 123. Bristol Myers Squibb Anti-PD-1 MAb SWOT Analysis
Table 124. Bristol Myers Squibb Recent Developments
Table 125. Merck Company Information
Table 126. Merck Description and Overview
Table 127. Merck Anti-PD-1 MAb Sales Quantity (KG), Revenue (US$ Million), Average Selling Price (ASP) (USD/KG) and Gross Margin (2018-2024)
Table 128. Merck Anti-PD-1 MAb Product and Services
Table 129. Merck Anti-PD-1 MAb SWOT Analysis
Table 130. Merck Recent Developments
Table 131. Junshi Pharma Company Information
Table 132. Junshi Pharma Description and Overview
Table 133. Junshi Pharma Anti-PD-1 MAb Sales Quantity (KG), Revenue (US$ Million), Average Selling Price (ASP) (USD/KG) and Gross Margin (2018-2024)
Table 134. Junshi Pharma Anti-PD-1 MAb Product and Services
Table 135. Junshi Pharma Anti-PD-1 MAb SWOT Analysis
Table 136. Junshi Pharma Recent Developments
Table 137. Innovent Biologics Inc Company Information
Table 138. Innovent Biologics Inc Description and Overview
Table 139. Innovent Biologics Inc Anti-PD-1 MAb Sales Quantity (KG), Revenue (US$ Million), Average Selling Price (ASP) (USD/KG) and Gross Margin (2018-2024)
Table 140. Innovent Biologics Inc Anti-PD-1 MAb Product and Services
Table 141. Innovent Biologics Inc Anti-PD-1 MAb SWOT Analysis
Table 142. Innovent Biologics Inc Recent Developments
Table 143. Hengrui Medicine Company Information
Table 144. Hengrui Medicine Description and Overview
Table 145. Hengrui Medicine Anti-PD-1 MAb Sales Quantity (KG), Revenue (US$ Million), Average Selling Price (ASP) (USD/KG) and Gross Margin (2018-2024)
Table 146. Hengrui Medicine Anti-PD-1 MAb Product and Services
Table 147. Hengrui Medicine Anti-PD-1 MAb SWOT Analysis
Table 148. Hengrui Medicine Recent Developments
Table 149. Beijing Beigene Company Information
Table 150. Beijing Beigene Description and Overview
Table 151. Beijing Beigene Anti-PD-1 MAb Sales Quantity (KG), Revenue (US$ Million), Average Selling Price (ASP) (USD/KG) and Gross Margin (2018-2024)
Table 152. Beijing Beigene Anti-PD-1 MAb Product and Services
Table 153. Beijing Beigene Anti-PD-1 MAb SWOT Analysis
Table 154. Beijing Beigene Recent Developments
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Anti-PD-1 MAb Distributors List
Table 158. Anti-PD-1 MAb Customers List
Table 159. Anti-PD-1 MAb Market Trends
Table 160. Anti-PD-1 MAb Market Drivers
Table 161. Anti-PD-1 MAb Market Challenges
Table 162. Anti-PD-1 MAb Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-PD-1 MAb Product Picture
Figure 2. Global Anti-PD-1 MAb Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Anti-PD-1 MAb Market Share by Type in 2022 & 2034
Figure 4. 40mg Product Picture
Figure 5. 100mg Product Picture
Figure 6. 200mg Product Picture
Figure 7. Others Product Picture
Figure 8. Global Anti-PD-1 MAb Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Anti-PD-1 MAb Market Share by Application in 2022 & 2034
Figure 10. Melanoma Patients
Figure 11. Lung Cancer Patients
Figure 12. Lymphoma Patients
Figure 13. Other
Figure 14. Anti-PD-1 MAb Report Years Considered
Figure 15. Global Anti-PD-1 MAb Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Anti-PD-1 MAb Revenue 2018-2034 (US$ Million)
Figure 17. Global Anti-PD-1 MAb Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 18. Global Anti-PD-1 MAb Sales Quantity 2018-2034 (KG)
Figure 19. Global Anti-PD-1 MAb Sales Quantity Market Share by Region (2018-2024)
Figure 20. Global Anti-PD-1 MAb Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Anti-PD-1 MAb Sales Quantity YoY (2018-2034) & (KG)
Figure 22. North America Anti-PD-1 MAb Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Anti-PD-1 MAb Sales Quantity YoY (2018-2034) & (KG)
Figure 24. Europe Anti-PD-1 MAb Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Anti-PD-1 MAb Sales Quantity YoY (2018-2034) & (KG)
Figure 26. China Anti-PD-1 MAb Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Anti-PD-1 MAb Sales Quantity YoY (2018-2034) & (KG)
Figure 28. APAC Anti-PD-1 MAb Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity YoY (2018-2034) & (KG)
Figure 30. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Anti-PD-1 MAb Sales Quantity in 2022
Figure 32. The Top 10 and Top 5 Players Market Share by Anti-PD-1 MAb Revenue in 2022
Figure 33. Anti-PD-1 MAb Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global Anti-PD-1 MAb Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Anti-PD-1 MAb Revenue Market Share by Type (2018-2034)
Figure 36. Global Anti-PD-1 MAb Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Anti-PD-1 MAb Revenue Market Share by Application (2018-2034)
Figure 38. North America Anti-PD-1 MAb Revenue Market Share by Company in 2022
Figure 39. North America Anti-PD-1 MAb Sales Quantity Market Share by Company in 2022
Figure 40. North America Anti-PD-1 MAb Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Anti-PD-1 MAb Revenue Market Share by Type (2018-2034)
Figure 42. North America Anti-PD-1 MAb Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Anti-PD-1 MAb Revenue Market Share by Application (2018-2034)
Figure 44. North America Anti-PD-1 MAb Revenue Share by Country (2018-2034)
Figure 45. North America Anti-PD-1 MAb Sales Quantity Share by Country (2018-2034)
Figure 46. United States Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Anti-PD-1 MAb Sales Quantity Market Share by Company in 2022
Figure 49. Europe Anti-PD-1 MAb Revenue Market Share by Company in 2022
Figure 50. Europe Anti-PD-1 MAb Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Anti-PD-1 MAb Revenue Market Share by Type (2018-2034)
Figure 52. Europe Anti-PD-1 MAb Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Anti-PD-1 MAb Revenue Market Share by Application (2018-2034)
Figure 54. Europe Anti-PD-1 MAb Revenue Share by Country (2018-2034)
Figure 55. Europe Anti-PD-1 MAb Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 57. France Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 61. China Anti-PD-1 MAb Sales Quantity Market Share by Company in 2022
Figure 62. China Anti-PD-1 MAb Revenue Market Share by Company in 2022
Figure 63. China Anti-PD-1 MAb Sales Quantity Market Share by Type (2018-2034)
Figure 64. China Anti-PD-1 MAb Revenue Market Share by Type (2018-2034)
Figure 65. China Anti-PD-1 MAb Sales Quantity Market Share by Application (2018-2034)
Figure 66. China Anti-PD-1 MAb Revenue Market Share by Application (2018-2034)
Figure 67. APAC Anti-PD-1 MAb Sales Quantity Market Share by Company in 2022
Figure 68. APAC Anti-PD-1 MAb Revenue Market Share by Company in 2022
Figure 69. APAC Anti-PD-1 MAb Sales Quantity Market Share by Type (2018-2034)
Figure 70. APAC Anti-PD-1 MAb Revenue Market Share by Type (2018-2034)
Figure 71. APAC Anti-PD-1 MAb Sales Quantity Market Share by Application (2018-2034)
Figure 72. APAC Anti-PD-1 MAb Revenue Market Share by Application (2018-2034)
Figure 73. APAC Anti-PD-1 MAb Revenue Share by Region (2018-2034)
Figure 74. APAC Anti-PD-1 MAb Sales Quantity Share by Region (2018-2034)
Figure 75. Japan Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 76. South Korea Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 77. China Taiwan Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 78. Southeast Asia Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 79. India Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 80. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue Market Share by Company in 2022
Figure 82. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Anti-PD-1 MAb Sales Quantity Share by Country (2018-2034)
Figure 87. Middle East, Africa and Latin America Anti-PD-1 MAb Revenue Share by Country (2018-2034)
Figure 88. Brazil Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 89. Mexico Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 90. Turkey Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 91. Israel Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 92. GCC Countries Anti-PD-1 MAb Revenue (2018-2034) & (US$ Million)
Figure 93. Anti-PD-1 MAb Value Chain
Figure 94. Anti-PD-1 MAb Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed